AbbVie Inc (ABBV)vsExagen Inc (XGN)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
XGN
Exagen Inc
$4.29
-10.44%
HEALTHCARE · Cap: $112.83M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 91763% more annual revenue ($62.82B vs $68.38M). ABBV leads profitability with a 5.8% profit margin vs -29.5%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
XGN
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Margin of Safety
+50.8%
Fair Value
$6.71
Current Price
$4.29
$2.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
No standout strengths identified
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -193.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : XGN
Revenue growth of 11.7% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : XGN
The primary concerns for XGN are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while XGN is a turnaround play — different risk/reward profiles.
XGN carries more volatility with a beta of 2.02 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 29/100) and 12.4% revenue growth. XGN offers better value entry with a 50.8% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Exagen Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Exagen Inc. develops and markets various test products based on its Cell-Bound Complement Activation Products technology under the AVISE brand name in the United States. The company is headquartered in Vista, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?